Abstracts re-analysed if not analysed by intention-to-treat. The summary effect estimate (Relative Risk, RR) was calculated by meta-analysis using a fixed effects model by the Mantel-Haenszel method. The quality of RCTs included in the meta-analysis was judged according to the method of randomisation and concealment of allocation of treatments (as this is the element of RCT design likely to introduce the most bias). Publication bias was assessed using funnel plots. RESULTS: Of the 133 papers initially identified in the literature search, only 8 were found to be head-tohead comparisons of a standard dose of PPI compared with esomeprazole 40 mg. This total was reduced to six when the quality of the RCTs was assessed. From the 6 trials, a metaanalysis of endoscopic healing rates of esomeprazole 40 mg compared with standard-dose PPIs gave the following RESULTS: At 4 weeks, RR 0.92 (95% CI: 0.90 to 0.94, p < 0.00001); at 8 weeks, RR 0.95 (95% CI: 0.94 to 0.97, p < 0.00001). The effect of using all eight trials in the meta-analysis made small numerical differences to the overall estimates but did not change the direction or make a significant difference non-significant. Publication bias did not appear to have a significant impact on the results, as there was no apparent asymmetry identified in the assessment of funnel plots. CONCLUSIONS: Esomeprazole demonstrates significantly higher endoscopic healing rates when compared to standard-dose PPIs. OBJECTIVE: To show the efficacy of orally administered esomeprazole 40 mg (ESO) in patients with erosive gastrooesophageal reflux disease (GERD) in Mexico. METHODS:
re-analysed if not analysed by intention-to-treat. The summary effect estimate (Relative Risk, RR) was calculated by meta-analysis using a fixed effects model by the Mantel-Haenszel method. The quality of RCTs included in the meta-analysis was judged according to the method of randomisation and concealment of allocation of treatments (as this is the element of RCT design likely to introduce the most bias). Publication bias was assessed using funnel plots. RESULTS: Of the 133 papers initially identified in the literature search, only 8 were found to be head-tohead comparisons of a standard dose of PPI compared with esomeprazole 40 mg. This total was reduced to six when the quality of the RCTs was assessed. From the 6 trials, a metaanalysis of endoscopic healing rates of esomeprazole 40 mg compared with standard-dose PPIs gave the following RESULTS: At 4 weeks, RR 0.92 (95% CI: 0.90 to 0.94, p < 0.00001); at 8 weeks, RR 0.95 (95% CI: 0.94 to 0.97, p < 0.00001). The effect of using all eight trials in the meta-analysis made small numerical differences to the overall estimates but did not change the direction or make a significant difference non-significant. Publication bias did not appear to have a significant impact on the results, as there was no apparent asymmetry identified in the assessment of funnel plots. CONCLUSIONS: Esomeprazole demonstrates significantly higher endoscopic healing rates when compared to standard-dose PPIs. We conducted an open label, prospective cohort study in 22 centers in Mexico, between June 2001 and July 2002, with patients being 18-86 years old, diagnosed with endoscopy-confirmed erosive (GERD) and classified according to Los Angeles Classification (LAC). Patients were treated with ESO 40 mg for a 4-8 week period. According to LAC, effectiveness was measured by the reflux-oesophagitis healing at 4 and 8 weeks, defined as the absence of macroscopic mucosal lesions. Symptoms and general evaluation of the treatment were secondary end points. Presence of Helicobacter pylori was assessed by clotest. The study was analyzed using the ITT population. Healing at the 4 and 8 week endpoints was assessed with the McNemar test (p < 0.05, 95% CI). RESULTS: A total of 213 patients were included in the study: 53.52% were males, and the average age was 44.2 years (±14.63). 78.88% were diagnosed with mild to moderated GERD (Grades A & B LAC), and 38.97% were positive for Helicobacter pylori. Using gastro-oesophageal endoscopy as the assessment method, GERD healing rate after the 4 and 8 weeks period with esomeprazole 40 mg were 88.73% (84.48%-92.98%, 95% CI) and 94.84% (91.87%-97.81%, 95% CI) respectively. No serious adverse events were reported. Treatment with esomeprazole 40 mg was well tolerated. CON-CLUSIONS: Esomeprazole 40 mg proved to be effective and secure for the GERD treatment in the Mexican patients.
PGI3

EFFICACY OF ESOMEPRAZOL IN GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD) IN A MEXICAN POPULATION
PGI4 ESOMEPRAZOLE VERSUS OTHER PROTON-PUMP INHIBITORS (PPI): CLINICAL AND COST EFFECTIVENESS ANALYSIS
Kaczor M, Becla L, Pawlik D, Dardzinski W, Walczak J, Nogas G, Wojcik R, Zespol-Instytutu A Arcana Institute, Cracow, Poland OBJECTIVES: To compare the clinical and cost-effectiveness of esomeprazole and other PPI (omeprazole, lansoprazole, pantoprazole and rabeprazole) in patients with GERD. METHODS:
The clinical effectiveness analysis according Cochrane Collaboration guidelines was performed. Cost-effectiveness decision model was performed from a payer's perspective, with a time horizon of 8 weeks. RESULTS: 8, 13, 6, and 3 RCT comparing esomeprazole to lansoprazole, omeprazole, pantoprazole and raboprazole were included. Esomeprazole 40 mg was significantly more effective compared to lansoprazole 30 mg and omeprazole 20 mg in healing reflux esophagitis after 4 and 8 weeks (OR = 1.25 and 1.29 vs. lansoprazole; OR = 1.84 and 2.10 vs. omeprazole). Esomeprazole is also more effective than lansoprazole and omeprazole for variables evaluating reflux symptoms. Compared to pantoprazole 40 mg, esomeprazole 40 mg was statistically significantly more effective in terms of healing erosive oesophagitis after 4-6 and 8-10 weeks (OR = 1.35 and 1.36, respectively), time to reach sustained heartburn resolution and proportion of heartburn-free days. Result of a single trial showed that pantoprazole resulted in faster first-time relief from GERD-related symptoms than esomeprazole. Based on a single study comparing esomeprazole 20 mg and rabeprazole 10 mg in patients with non-erosive GERD, both treatments had similar efficacy in relief of symptoms. Triple therapy regimens with either esomeprazole or omeprazole were similarly effective in eradicating Helicobacter pylori. The safety analysis showed no significant differences in the frequency of adverse events between esompeprazole and other PPI except for headaches, which occurred more frequently in the desloratadine group than in the lansoprazole group. The ICER for esomeprazole per additional patient healed after 8 weeks was 7858 PLN (vs lansoprazole), 2608 PLN (vs lansoprazole) and 6274 PLN (vs. pantoprazole). CONCLUSIONS: Esomeprazole is at least as effective as other PPI in the treatment of GERD.
PGI5 GASTROINTESTINAL MEDICATION USE AND COSTS IN HEART TRANSPLANT RECIPIENTS RECEIVING MYCOPHENOLATE MOFETIL
Legorreta AP 1 , Gilmore AS 2 , Marehbian J 2 , Naujoks C 3 , Kilburg A 3 1 UCLA School of Public Health, Los Angeles, CA, USA, 2 Health Benchmarks, Inc, Woodland Hills, CA, USA, 3 Novartis Pharma AG, Basel, Switzerland OBJECTIVES: Mycophenolate mofetil (MMF) has been associated with increased risk of gastrointestinal (GI) complications in transplant recipients. Our aim was to assess the risk of GI medication use in heart transplant patients receiving MMF and their health care costs over a two-year period. METHODS: US commercial claims data for 233 patients receiving heart transplants between 1995 and 2005 were linked to data from the Organ Procurement Transplant Network. Patients were placed into two groups: received MMF (MMF group) and did not (non-MMF group). MMF recipients were identified as having ≥1 pharmacy claim post-transplant for MMF. For the MMF group, use of GI medications was defined as having ≥1 prescription (H2 antagonists, proton pump inhibitors, and miscellaneous GI agents) during the year following the initial claim for MMF. For those in the non-MMF group, the commensurate 1-year period posttransplant in which the GI claim occurred was defined based on the median time to the first MMF claim of the MMF group. A multivariate logistic regression and a Wilcoxon test were employed to assess risk of GI medication use and total medical costs 1 year before and after occurrence of GI medication claim, respectively. RESULTS: MMF was received by 173 (74%) patients. GI medication use occurred in 139 (80%) of the patients in the MMF group and in 29 (48%) of the patients in the non-MMF group. Patients who received MMF were associated with a statistically significant increase in risk of GI medication use compared to patients who did not receive MMF (OR = 7.65, p < 0.0001). Patients using GI medications generated significantly greater costs compared to patients not using GI medications ($69,328 vs $48,301, p < 0.0001). CONCLUSIONS: Heart transplant recipients who receive MMF had 7.7 times greater risk of using GI medications compared to those who did not receive MMF, which leads to increased costs.
PGI6 THE USE OF BUDGET IMPACT MODELLING TO ASSESS THE ECONOMIC CONSEQUENCE OF CHANGING THE PRESCRIPTION PATTERN OF PROTON PUMP INHIBITORS (PPI) IN SWEDEN
Hjelmgren J 1 , Persson U 2
1
The Swedish Institute for Health Economics, IHE, Lund, Sweden, 2 The Swedish Institute for Health conomics, IHE, Lund, Sweden OBJECTIVE: To assess the economic consequences of changing the prescription pattern of proton pump inhibitors (PPI) in Sweden by use of a budget impact model (BIM). METHODS: Data from published sources provided information about treatment effects of different PPIs and productivity losses due to upper gastrointestinal symptoms (GIS). Sale statistics at the county council level and official Swedish price lists were used to estimate drug costs. Data on wages ware taken from Statistics Sweden and was used to estimate indirect costs. The BIM was flexible and allowed us to analyse (i) the drug budget impact in a particular county council of switching between different PPIs and (ii) the annual per patient drug cost and the indirect cost from treating patients with different PPIs during a specific time period. RESULTS: In the county council of Stockholm (1.9 million inhabitants) the annual PPI drug costs amount to about €11.5 Million of which 50% and 14% comprise of generic omeprazole and esomeprazole, respectively. The consequence of switching from generic omeprazole to esomeprazole for 30% of the patients would result in increasing the PPI drug costs by 11%. However, as the major part of the annual per patient costs comprise of indirect costs due to productivity losses and absence from work, esomeprazole only need to be 1-2 percent units more effective in reducing GIS per week than generic omeprazole to compensate for its higher price. CONCLUSION: The results indicate the importance of including both direct and indirect costs in BIMs when analyzing changes in drug prescription patterns.
PGI7
COST-EFFECTIVENESS OF A POTENTIAL FUTURE HELICOBACTER PYLORI VACCINE IN THE NETHERLANDS
De Vries R 1 , Klok RM 1 , Brouwers J 1 , Postma MJ 2 1 University of Groningen, Groningen, The Netherlands, 2 University of Groningen / Groningen University Institute for Drug Exploration (GUIDE), Groningen, The Netherlands OBJECTIVES: Infection with Helicobacter pylori (HP) is associated with several clinical conditions; the two most important in both numbers and costs are peptic ulcer disease and gastric cancer. In 1999 these two conditions were responsible for more than 2000 deaths and €94.9 million of direct medical costs in The Netherlands. A great step forward would be the development of a preventive vaccine. The objective of this study is to estimate the cost-effectiveness of a potential HP vaccine for The Netherlands. METHODS: We designed a probabilistic Markov model to fully incorporate the uncertainty associated with the different transition probabilities. The model followed a birth cohort during a period of 85 years. Transition probabilities for the current situation without vaccination were based on Dutch data. In presence of vaccination these probabilities were adjusted using the attributive risks and vaccine efficacy. Vaccine efficacy was assumed at 80% (range: 50-100). The perspective of the analysis was that of the health care sector; only Dutch direct medical costs were taken into account. For cost per dose we performed different scenario analyses (base case: €50). For each scenario we conducted 10.000 Monte Carlo simulations. Costeffectiveness is expressed as net costs per life year gained (LYG) where costs and effects were discounted according to the current Dutch guidelines for pharmacoeconomic research (costs: 4%, effects: 1.5%). RESULTS: For the base case scenario the median cost-effectiveness ratio is estimated €2700 per LYG. For all scenarios investigated cost-effectiveness is estimated below the informal Dutch threshold of €20,000 per LYG with a probability of more than 0.95. CONCLUSIONS: According to our model, for the greater part based on Dutch data, a potential new developed HP vaccine could be considered cost-effective as the cost-effectiveness is estimated below the informal Dutch threshold used by decision makers.
PGI8
COST-EFFECTIVENESS ANALYSIS OF ROTAVIRUS VACCINATION PROGRAMME IN THE UK
Largeron N 1 , Trichard M 2 , Miadi-Fargier H 3 , Trancard A 3 , D'Ausilio A 4 , Chicoye A 5 1 sanofi pasteur MSD, Lyon, France, 2 sanofi pasteur MSD, Lyon, France, France, 3 AREMIS-aegisnet, Neuilly sur Seine, France, 4 Fourth Hurdleaegisnet, London, UK, 5 AREMIS-aegisnet, Neuilly-sur-Seine, France OBJECTIVES: A pentavalent rotavirus vaccine to prevent rotavirus gastroenteritis (RVGE) in children will soon become available. The objective of the study reported here was to assess the health outcomes and the economic impact in the UK of a RV vaccination programme vs no programme. METHODS: A birth cohort was followed up to age 5 using a cohort model. Epidemiological parameters were taken from the REVEAL study (a prospective epidemiological study conducted in the UK, [2004] [2005] and from literature. Costs were assessed from NHS and societal perspectives by combining health care resource utilization collected in REVEAL study and unit costs from official sources. ITT effectiveness of the vaccine was taken from a large worldwide clinical trial (70,000 children). Health outcomes included home care cases, telephone consultations, GP/Acci-dent&Emergency department visits, hospitalisations and nosocomial infections. A sensitivity analysis was performed varying the cost of the RV vaccine course between £80 and £100. RESULTS: The model estimates that the introduction of a RV vaccination programme with the pentavalent RV vaccine (90% coverage rate) would reduce the RVGE burden by 75% in the UK: 102,290 home care cases, 25,570 telephone consultations, 83,220 GP visits, 5660 Accident&Emergency department visits, 12,220 hospitalisations and 5040 nosocomial infections could be avoided. The RVGE cost was estimated at £29m and £69m from NHS and societal perspectives respectively. The introduction of a RV vaccination programme would reduce the RVGE cost by about 75% in both perspectives. For a vaccine course ranging from £80 to £100, the RV vaccination programme is associated with an incremental cost-effectiveness ratio that varies from
